Paradigm Biopharma - Termination of coverage
Edison Investment Research is terminating coverage on Atlantis Japan Growth Fund (AJG), Paradigm Biopharma (PAR), The European Smaller Companies...
317 Views
Paradigm Biopharma - Q1 results recap iPPS progress in OA & MPS
Paradigm announced Q1 results (for the quarter ending 30 September) and a A$30m capital raise to potentially extend its cash runway through to mid...
406 Views
Paradigm Biopharma - Disease modifying properties in iPPS Phase II
Paradigm reported favourable quantitative MRI data from the six-month analysis of the Phase II trial (PARA OA 008) evaluating a single six-week...
258 Views
Paradigm Biopharma - Durable responses observed for kOA
Paradigm has announced positive day-365 data from its Phase II trial (PARA_OA_008) assessing injectable pentosan polysulfate (iPPS) as a...
252 Views
Paradigm Biopharma - Progressing toward key near-term objectives
Paradigm has shared its June 2023 quarterly update. In Q423, net cash outflow from operating activities was A$17.1m (up from A$10.3m in Q323) or...
196 Views